Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990880 · ClinicalTrials.gov registry record · Phase 1
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
A Phase 1 study of Neoplasms Prostate, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 5
- Study locations
NCT06990880: Recruiting Phase 1 study of Neoplasms Prostate, sponsored by GlaxoSmithKline.
NCT06990880 is a Phase 1 study of Neoplasms Prostate that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 85 participants, below the 3,094-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06990880, a Phase 1 study of Neoplasms Prostate, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Conditions Studied
Interventions
- DRUG GSK5458514
Study Locations (5)
Other
- GSK Investigational Site - Tokyo
- GSK Investigational Site - Tokyo
Colorado
- GSK Investigational Site - Denver
Tennessee
- GSK Investigational Site - Nashville
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2028-08-09 |
| Phase | Phase 1 |
What NCT06990880 shows while recruiting
NCT06990880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 3,094-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neoplasms Prostate appearing as the primary indexed condition, and to 1 intervention - of which GSK5458514 is the first listed.
NCT06990880 lists 5 locations in 4 states (Other, Colorado, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06990880 about?
NCT06990880 is a clinical study titled "A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer". The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
What is the current status of trial NCT06990880?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2025-06-12. Estimated completion is 2028-08-09.
What conditions does trial NCT06990880 study?
This clinical trial studies the following conditions: Neoplasms Prostate.
What interventions are being tested in trial NCT06990880?
The interventions under investigation include: GSK5458514 (DRUG).
Who is sponsoring clinical trial NCT06990880?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990880 being conducted?
This trial has 5 study locations across Colorado, Tennessee, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
RECRUITING · Phase 1
-
MRI/Ultrasound Fusion Guided Prostate Cryotherapy
RECRUITING
-
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
RECRUITING
-
Investigation of Impact of AI on Prostate Cancer Workflow
RECRUITING · NA
-
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
COMPLETED · Phase 4
-
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI